What is Prenetics Ltd's earnings per share (EPS)?

Prenetics Ltd (PRE) reported diluted earnings per share of $-2.46 for fiscal year 2025. This represents a 33.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Prenetics Ltd Financials

PRE

Source SEC Filings (10-K/10-Q) Updated Apr 30, 2026 Currency USD FYE April

This page shows Prenetics Ltd (PRE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PRE FY2025 2026-04-30

Prenetics’ visible operating pattern today is rapid revenue scaling still financed by equity-supported cash burn, not by internally generated cash.

Revenue scaled sharply, and net margin improved to -43.3% from -162.7%, showing losses are shrinking faster as sales rise, but not yet enough to create positive cash generation. But cash burn still came from operations, not reinvestment: operating cash flow was -$21.8M and free cash flow -$22.0M, so the outflow reflects an unprofitable core more than a capital-heavy buildout.

Leverage is minimal—long-term debt was only $437K against cash of $32.1M—so creditors are not the main source of pressure. That posture matters because the balance sheet remains equity-financed; the business challenge is operating self-sufficiency rather than servicing a heavy debt load.

Cash fell from $52.3M to $32.1M even with fresh financing, which means outside capital offset rather than solved the operating drain. At the same time, receivables stayed below the prior year while revenue accelerated, so working capital was not the main reason cash left the business.

Financial Health Signals

Financial Profile 43/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Prenetics Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

100

Prenetics Ltd's revenue surged 201.7% year-over-year to $92.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

100

Prenetics Ltd carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Prenetics Ltd's current ratio of 2.97 indicates adequate short-term liquidity, earning a score of 57/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Prenetics Ltd generated -$21.8M in operating cash flow, capex of $208K consumed most of it, leaving -$22.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Prenetics Ltd generates a -25.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -29.1% the prior year.

Piotroski F-Score Neutral

5/9

Prenetics Ltd passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.55x

For every $1 of reported earnings, Prenetics Ltd generates $0.55 in operating cash flow (-$21.8M OCF vs -$40.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$92.4M

YoY+201.7%

5Y CAGR+7.2%

Prenetics Ltd generated $92.4M in revenue in fiscal year 2025. This represents an increase of 201.7% from the prior year.

EBITDA

N/A

Net Income

-$40.0M

YoY+19.7%

Prenetics Ltd reported -$40.0M in net income in fiscal year 2025. This represents an increase of 19.7% from the prior year.

EPS (Diluted)

$-2.46

YoY+33.7%

Prenetics Ltd earned $-2.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 33.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$22.0M

YoY+26.3%

Prenetics Ltd generated -$22.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 26.3% from the prior year.

Cash & Debt

$32.1M

YoY-38.5%

5Y CAGR+17.3%

Prenetics Ltd held $32.1M in cash against $437K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

17M

YoY+30.0%

Prenetics Ltd had 17M shares outstanding in fiscal year 2025. This represents an increase of 30.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

-43.3%

YoY+119.4pp

5Y CAGR-40.3pp

Prenetics Ltd's net profit margin was -43.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 119.4 percentage points from the prior year.

Return on Equity

-25.6%

YoY+3.5pp

5Y CAGR-19.2pp

Prenetics Ltd's ROE was -25.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.5 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$639K

Prenetics Ltd spent $639K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$208K

YoY-79.3%

5Y CAGR-40.8%

Prenetics Ltd invested $208K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 79.3% from the prior year.

PRE Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$92.4M+201.7%	$30.6M+40.8%	$21.7M+65.2%	$13.2M+5.0%	$12.5M-80.8%	$65.2M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$241K+18.7%	$203K-16.1%	$242K-0.8%	$244K+18.5%	$206K+316.8%	$49K
Income Tax	$34K+100.4%	-$7.9M-2827.1%	-$269K-9.8%	-$245K-109.5%	$2.6M+232.6%	-$1.9M
Net Income	-$40.0M+19.7%	-$49.8M+23.1%	-$64.8M+66.0%	-$190.5M-9.4%	-$174.0M-8760.8%	-$2.0M
EPS (Diluted)	$-2.46+33.7%	$-3.71+23.2%	$-4.83	$-44.50+80.2%	$-225.17	N/A

Metric	Q3'25	Q3'24	Q3'23	Q3'22
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A

PRE Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$206.1M-3.5%	$213.6M-16.0%	$254.2M-18.6%	$312.1M+110.2%	$148.5M	N/A
Current Assets	$85.2M-1.1%	$86.1M-8.0%	$93.7M-61.3%	$241.8M+126.2%	$106.9M	N/A
Cash & Equivalents	$32.1M-38.5%	$52.3M+14.3%	$45.7M-68.8%	$146.7M+315.6%	$35.3M+143.5%	$14.5M
Inventory	$7.0M+7.1%	$6.6M+110.0%	$3.1M-31.0%	$4.5M-33.6%	$6.8M	N/A
Accounts Receivable	$14.8M-11.5%	$16.8M-5.0%	$17.7M-66.8%	$53.2M-3.1%	$54.9M	N/A
Goodwill	$1.4M-96.3%	$37.4M+28.1%	$29.2M-13.7%	$33.8M+749.7%	$4.0M-0.4%	$4.0M
Total Liabilities	$49.7M+17.7%	$42.2M-4.1%	$44.0M-35.9%	$68.7M-87.5%	$549.4M	N/A
Current Liabilities	$28.7M-21.4%	$36.6M-7.4%	$39.5M-31.0%	$57.2M-2.6%	$58.7M	N/A
Long-Term Debt	$437K-85.5%	$3.0M+247.6%	$867K-77.0%	$3.8M+4.5%	$3.6M	N/A
Total Equity	$156.4M-8.7%	$171.3M-18.5%	$210.2M-13.7%	$243.5M+160.7%	-$400.9M-1392.9%	$31.0M
Retained Earnings	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q3'23	Q3'22
Total Assets	$213.6M-16.0%	$254.2M-18.6%	$312.1M+110.2%	$148.5M
Current Assets	$86.1M-8.0%	$93.7M-61.3%	$241.8M+126.2%	$106.9M
Cash & Equivalents	$52.3M+14.3%	$45.7M-68.8%	$146.7M+315.6%	$35.3M
Inventory	$6.6M+110.0%	$3.1M-31.0%	$4.5M-33.6%	$6.8M
Accounts Receivable	$16.8M-5.0%	$17.7M-66.8%	$53.2M-3.1%	$54.9M
Goodwill	$37.4M+28.1%	$29.2M-13.7%	$33.8M+749.7%	$4.0M
Total Liabilities	$42.2M-4.1%	$44.0M-35.9%	$68.7M-87.5%	$549.4M
Current Liabilities	$36.6M-7.4%	$39.5M-31.0%	$57.2M-2.6%	$58.7M
Long-Term Debt	$3.0M+247.6%	$867K-77.0%	$3.8M+4.5%	$3.6M
Total Equity	$171.3M-18.5%	$210.2M-13.7%	$243.5M+160.7%	-$400.9M
Retained Earnings	N/A	N/A	N/A	N/A

PRE Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$21.8M+24.4%	-$28.9M-109.8%	-$13.8M-194.8%	$14.5M+8.2%	$13.4M+565.9%	-$2.9M
Capital Expenditures	$208K-79.3%	$1.0M+191.6%	$345K-93.0%	$4.9M-42.1%	$8.5M+198.5%	$2.9M
Free Cash Flow	-$22.0M+26.3%	-$29.9M-111.8%	-$14.1M-247.5%	$9.6M+96.5%	$4.9M+184.8%	-$5.7M
Investing Cash Flow	-$35.7M-192.6%	$38.5M+146.5%	-$83.0M-79.8%	-$46.1M-109.5%	-$22.0M-268.6%	-$6.0M
Financing Cash Flow	$37.5M+1220.8%	-$3.3M+28.9%	-$4.7M-103.3%	$143.3M+388.9%	$29.3M+147.5%	$11.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$639K	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q3'23	Q3'22
Operating Cash Flow	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

PRE Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-43.3%+119.4pp	-162.7%+135.3pp	-297.9%+1148.9pp	-1446.8%-58.3pp	-1388.5%-1385.5pp	-3.0%
Return on Equity	-25.6%+3.5pp	-29.1%+1.7pp	-30.8%+47.4pp	-78.2%	N/A	-6.3%
Return on Assets	-19.4%+3.9pp	-23.3%+2.2pp	-25.5%+35.5pp	-61.0%+56.2pp	-117.2%	N/A
Current Ratio	2.97+0.6	2.36-0.0	2.37-1.9	4.23+2.4	1.82	N/A
Debt-to-Equity	0.00-0.0	0.02+0.0	0.00-0.0	0.02+0.0	-0.01	N/A
FCF Margin	-23.8%+73.7pp	-97.6%-32.7pp	-64.9%-137.6pp	72.7%+33.8pp	38.9%+47.7pp	-8.8%

Metric	Q3'25	Q3'24	Q3'23	Q3'22
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A
Current Ratio	2.36-0.0	2.37-1.9	4.23+2.4	1.82
Debt-to-Equity	0.02+0.0	0.00-0.0	0.02+0.0	-0.01
FCF Margin	N/A	N/A	N/A	N/A

Similar Companies

Burning Rock Biotech Ltd BNR

$176.1M

$118.8M

$43.6M

$84.3M

$144.0M

Frequently Asked Questions

What is Prenetics Ltd's annual revenue?

Prenetics Ltd (PRE) reported $92.4M in total revenue for fiscal year 2025. This represents a 201.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Prenetics Ltd's revenue growing?

Prenetics Ltd (PRE) revenue grew by 201.7% year-over-year, from $30.6M to $92.4M in fiscal year 2025.

Is Prenetics Ltd profitable?

No, Prenetics Ltd (PRE) reported a net income of -$40.0M in fiscal year 2025, with a net profit margin of -43.3%.

How much debt does Prenetics Ltd have?

As of fiscal year 2025, Prenetics Ltd (PRE) had $32.1M in cash and equivalents against $437K in long-term debt.

What is Prenetics Ltd's net profit margin?

Prenetics Ltd (PRE) had a net profit margin of -43.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Prenetics Ltd's return on equity (ROE)?

Prenetics Ltd (PRE) has a return on equity of -25.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Prenetics Ltd's free cash flow?

Prenetics Ltd (PRE) generated -$22.0M in free cash flow during fiscal year 2025. This represents a 26.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Prenetics Ltd's operating cash flow?

Prenetics Ltd (PRE) generated -$21.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Prenetics Ltd's total assets?

Prenetics Ltd (PRE) had $206.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Prenetics Ltd's capital expenditures?

Prenetics Ltd (PRE) invested $208K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Prenetics Ltd buy back shares?

Yes, Prenetics Ltd (PRE) spent $639K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Prenetics Ltd have outstanding?

Prenetics Ltd (PRE) had 17M shares outstanding as of fiscal year 2025.

What is Prenetics Ltd's current ratio?

Prenetics Ltd (PRE) had a current ratio of 2.97 as of fiscal year 2025, which is generally considered healthy.

What is Prenetics Ltd's debt-to-equity ratio?

Prenetics Ltd (PRE) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Prenetics Ltd's return on assets (ROA)?

Prenetics Ltd (PRE) had a return on assets of -19.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Prenetics Ltd's cash runway?

Based on fiscal year 2025 data, Prenetics Ltd (PRE) had $32.1M in cash against an annual operating cash burn of $21.8M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Prenetics Ltd's Piotroski F-Score?

Prenetics Ltd (PRE) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Prenetics Ltd's earnings high quality?

Prenetics Ltd (PRE) has an earnings quality ratio of 0.55x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Prenetics Ltd?

Prenetics Ltd (PRE) scores 43 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.